Previous clinical data also showed reduced CRP and collagen mediated platelet aggregation in ibrutinib-treated CLL patients, while healthy individuals did not experience bleeding issues with ibrutinib [14,31]. Here, CRP is linked to B-cell chronic lymphocytic leukemia.